This episode delivers the definitive mechanistic tour: ibogaine is a textbook "dirty drug" acting across many targets. The hosts enumerate its bindings — NMDA antagonism, α3β4 nicotinic acetylcholine receptor antagonism (the leading anti-addiction hypothesis), κ- and μ-opioid activity, σ1/σ2, and SERT/monoamines — and weigh their relative importance. Neurotrophic effects (GDNF/BDNF) and the psychoplastogen concept are introduced. Noribogaine, the long-lived O-demethylated metabolite, is given equal weight, with CYP2D6 polymorphism explaining interindividual exposure variability. The discussion of pharmacokinetics — lipophilicity, accumulation, duration — ties mechanism to the observed addiction-interruption phenomenon and bridges to the safety episode that follows.